Form D · Biotechnology
Aliada Therapeutics, Inc.
Boston, MA · CIK 0001870878
Offering snapshot reported Dec 30, 2022 · SEC filing
- Reported sold
- $32M Offering amount: $32M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 23, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2022 | Initial | $31,999,994 | No comparison | 5 | SEC filing |
| Jul 7, 2021 | Initial | $1,000,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-469243
Source: Form D, filed Dec 30, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sari Epstein | Executive |
| Marian Nakada | Director |
| Joshua Resnick | Director |
| Adam J. Rosenberg | Director, Executive |
| Jim Sullivan | Director |
| Laura Tadvalkar | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Berkeley Street, 23rd Floor
Boston, MA, 02116
Boston, MA, 02116